Immune Thrombocytopenic Purpura | Topics

FDA Grants Fast Track Designation to Rilzabrutinib for Treatment of ITP
November 18, 2020

The FDA granted fast track designation to rilzabrutinib for the treatment of patients with immune thrombocytopenia.

I-WISh Survey Highlights ITP Issues for Patients and Physicians
November 09, 2020

The survey highlighted the need for further research into the specific effects of ITP in individual patients so that these findings can be better integrated into the management of this patient population.

Rituximab More Effective than Splenectomy for the Second-Line Treatment of Pediatric ITP
November 07, 2020

This study suggested that there is evidence, though low quality, that rituximab (Rituxan) may be a more effective second-line therapy than splenectomy for children with immune thrombocytopenia.